NCT07113808

Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China

Clinical Medical Quality Control Management of Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China: A Multi-Center Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 108 (estimated)
• Sponsor: The Children's Hospital of Zhejiang University School of Medicine · Academic / Other
• Sex: All
• Age: 29 Days – 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluate the application of intravenous contrast-enhanced ultrasound examination in children with intra-abdominal diseases that require clear diagnoses. The main questions it aims to answer are: * Is intravenous contrast-enhanced ultrasound helpful for the diagnosis of intra-abdominal diseases in children? * What medical problems do participants have when participating in intravenous contrast-enhanced ultrasound examination? * How can ultrasound doctors conduct intravenous contrast-enhanced ultrasound examinations in a standardized manner? Researchers will performing intravenous contrast-enhanced ultrasound examinations on participants and collecting research subjects to establish a multicenter clinical data database. Participants will: * Perform abdominal ultrasound examination to assess the condition. * At least conduct one intravenous contrast-enhanced ultrasound examination. Based on the result of the contrast examination, decide whether to conduct another examination. * Keep a diary of their symptoms and therapeutic process in 30 days.

Conditions

• Abdominal Neoplasm
• Abdominal Injury
• Ascites

Interventions

Type	Name	Description
DEVICE	contrast-enhanced ultrasound examination	to evaluate the the application of contrast-enhanced ultrasound examination in children with intra-abdominal diseases that require clear diagnoses aged from 29 days to 18 years old
DRUG	SonoVue®	perform contrast enhanced ultrasound (CEUS) using Sonovue as the contrast agent

Timeline

• Start date: 2024-09-10
• Primary completion: 2026-09-30
• Completion: 2026-09-30
• First posted: 2025-08-11
• Last updated: 2025-12-08

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study